The proteome is the entire complement of proteins expressed by a genome, cell, tissue or organism. More specifically, it is the expressed proteins at a given time point under defined conditions. The term is a blend of proteins and genome.
In a recent medRxiv research paper, the US scientists examined the effects of non-synonymous mutations in the circulating B.1.1.7 strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on linear antibody epitope signal for viral spike glycoprotein and nucleoprotein – and demonstrated that mutations should not result in immune evasion.
Bruker Corporation and Evosep today announced major progress in high-sensitivity, quantitative true single-cell proteomics, using a modified timsTOF Pro mass spectrometer connected to an Evosep One low-flow chromatography system.
Scientists from Würzburg and the US have charted the first global atlas of direct interactions between SARS-CoV-2 RNA and human host cells. This may provide a starting point for novel treatments.
Researchers in the United States and Australia have conducted a comprehensive analysis of the epitope recognition patterns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans.
In a recent study, researchers report how the SARS-CoV-2 proteome in 3D has evolved during the first six months of the COVID-19 pandemic.
A team of researchers at the School of Information Sciences in Illinois, USA, has revealed the rate of mutation in the 29 proteins that make up the SARS-CoV-2 microbe.
The replacement of lost neurons is a holy grail for neuroscience. A new promising approach is the conversion of glial cells into new neurons. Improving the efficiency of this conversion or reprogramming after brain injury is an important step towards developing reliable regenerative medicine therapies.
Researchers from the Huazhong University of Science and Technology and Shanghai Jiao Tong University, China, recently built a proteome microarray with 20 out of the 28 predicted SARS-CoV-2 proteins to help understand IgM/IgG responses specific to SARS-CoV-2.
A team of researchers in Europe has created a comprehensive data resource to help improve understanding of how coronavirus disease 2019 (COVID-19) progresses and how biomarkers could be used to guide treatment approaches and disease monitoring.
A research group in India has recently described how the field of proteomics could be pivotal in helping to tackle the current coronavirus disease 2019 (COVID-19) pandemic.
A new study published on the preprint server bioRxiv in November 2020 describes the virus's N protein as a promising epitope for serology.
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.
A team of researchers has conducted a study suggesting that the majority of the global population is likely to have pre-existing T-cell immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.
The Science and Technology Award recognizes an individual or team in private industry who played a key role in the commercialization of proteomics technology, product, or procedure.
Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.
Twenty years after the release of the human genome, the genetic "blueprint" of human life, an international research team, including the University of British Columbia's Chris Overall, has now mapped the first draft sequence of the human proteome.
The fight against bacterial infections, especially those caused by resistant pathogens, is in full swing with the search for new antibiotic agents.
Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.
An international team of scientists has identified novel T cell-recognized epitopes spanning different proteins of severe acute respiratory syndrome coronavirus 2 in COVID-19 recovered patients. The scientists have also revealed phenotypical characteristics of the T cell population.
Immune cells that can recognize residual HIV-infected cells in people living with HIV (PLWH) who take antiretroviral therapy (ART) remain active for years, says a new study published today in eLife.